 Aytan Musayeva
Concepts (166)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epithelium, Corneal | 7 | 2024 | 10 | 2.730 |
Why?
| | Cornea | 14 | 2025 | 51 | 2.090 |
Why?
| | Corneal Transplantation | 7 | 2024 | 7 | 1.860 |
Why?
| | Visual Acuity | 7 | 2024 | 143 | 1.430 |
Why?
| | Corneal Diseases | 5 | 2024 | 14 | 1.250 |
Why?
| | Corneal Edema | 3 | 2023 | 4 | 1.240 |
Why?
| | Dry Eye Syndromes | 3 | 2022 | 8 | 1.170 |
Why?
| | Retina | 3 | 2021 | 63 | 1.060 |
Why?
| | Limbus Corneae | 3 | 2024 | 8 | 0.990 |
Why?
| | Endothelium, Corneal | 3 | 2022 | 4 | 0.950 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 2 | 2022 | 2 | 0.930 |
Why?
| | Keratoconus | 1 | 2021 | 4 | 0.790 |
Why?
| | Pentacyclic Triterpenes | 1 | 2021 | 8 | 0.780 |
Why?
| | Goblet Cells | 1 | 2021 | 2 | 0.760 |
Why?
| | Receptor, Muscarinic M3 | 1 | 2021 | 7 | 0.760 |
Why?
| | Protective Agents | 1 | 2021 | 16 | 0.760 |
Why?
| | Conjunctiva | 1 | 2021 | 14 | 0.760 |
Why?
| | Mice, Inbred C57BL | 9 | 2025 | 1782 | 0.750 |
Why?
| | Fuchs' Endothelial Dystrophy | 1 | 2020 | 2 | 0.720 |
Why?
| | Reperfusion Injury | 1 | 2021 | 87 | 0.720 |
Why?
| | Acanthamoeba Keratitis | 1 | 2020 | 1 | 0.720 |
Why?
| | Eye Infections, Parasitic | 1 | 2020 | 2 | 0.720 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 122 | 0.700 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2018 | 15 | 0.630 |
Why?
| | Mice | 15 | 2025 | 5673 | 0.550 |
Why?
| | Graft Survival | 3 | 2024 | 153 | 0.500 |
Why?
| | Animals | 18 | 2025 | 13141 | 0.490 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2024 | 82 | 0.490 |
Why?
| | Graft Rejection | 3 | 2024 | 168 | 0.480 |
Why?
| | Tears | 4 | 2022 | 10 | 0.470 |
Why?
| | Cell Proliferation | 1 | 2018 | 987 | 0.470 |
Why?
| | Tissue Donors | 3 | 2024 | 111 | 0.430 |
Why?
| | Stem Cell Transplantation | 3 | 2024 | 179 | 0.390 |
Why?
| | Mice, Inbred BALB C | 4 | 2024 | 296 | 0.380 |
Why?
| | Arterioles | 3 | 2019 | 33 | 0.370 |
Why?
| | Reactive Oxygen Species | 3 | 2021 | 406 | 0.360 |
Why?
| | Retrospective Studies | 9 | 2024 | 6190 | 0.360 |
Why?
| | Disease Models, Animal | 4 | 2025 | 1419 | 0.360 |
Why?
| | Corneal Opacity | 2 | 2020 | 3 | 0.360 |
Why?
| | Astigmatism | 2 | 2020 | 5 | 0.360 |
Why?
| | Mice, Knockout | 4 | 2021 | 840 | 0.340 |
Why?
| | Male | 15 | 2025 | 25572 | 0.310 |
Why?
| | Follow-Up Studies | 4 | 2024 | 2188 | 0.310 |
Why?
| | Retinal Diseases | 2 | 2019 | 51 | 0.310 |
Why?
| | Trigeminal Ganglion | 2 | 2025 | 2 | 0.300 |
Why?
| | Receptors, Neurokinin-1 | 2 | 2025 | 10 | 0.300 |
Why?
| | Substance P | 2 | 2025 | 28 | 0.290 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2019 | 78 | 0.290 |
Why?
| | Vasodilation | 2 | 2019 | 98 | 0.290 |
Why?
| | Aged, 80 and over | 5 | 2020 | 3158 | 0.290 |
Why?
| | Stem Cells | 2 | 2024 | 171 | 0.260 |
Why?
| | Pain Perception | 1 | 2025 | 4 | 0.240 |
Why?
| | Integrin alpha Chains | 1 | 2024 | 9 | 0.240 |
Why?
| | Refraction, Ocular | 2 | 2022 | 7 | 0.230 |
Why?
| | Th1 Cells | 1 | 2024 | 53 | 0.230 |
Why?
| | Aged | 7 | 2024 | 9505 | 0.230 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 964 | 0.220 |
Why?
| | Mustard Gas | 1 | 2023 | 1 | 0.220 |
Why?
| | Corneal Ulcer | 1 | 2023 | 4 | 0.220 |
Why?
| | Tomography, Optical Coherence | 2 | 2021 | 107 | 0.220 |
Why?
| | Dendritic Cells | 1 | 2024 | 133 | 0.220 |
Why?
| | alpha-MSH | 1 | 2023 | 17 | 0.220 |
Why?
| | Cell Count | 2 | 2020 | 147 | 0.220 |
Why?
| | Humans | 16 | 2024 | 50201 | 0.220 |
Why?
| | Antigens, CD | 1 | 2024 | 216 | 0.220 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 252 | 0.220 |
Why?
| | Corneal Dystrophies, Hereditary | 1 | 2022 | 1 | 0.210 |
Why?
| | Trigeminal Nerve Diseases | 1 | 2022 | 3 | 0.210 |
Why?
| | Keratitis, Herpetic | 1 | 2022 | 2 | 0.210 |
Why?
| | Keratitis | 1 | 2022 | 10 | 0.210 |
Why?
| | Corneal Neovascularization | 1 | 2022 | 1 | 0.200 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2022 | 23 | 0.200 |
Why?
| | Descemet Membrane | 1 | 2021 | 2 | 0.200 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2023 | 129 | 0.200 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 73 | 0.200 |
Why?
| | Middle Aged | 6 | 2024 | 12356 | 0.190 |
Why?
| | Edema | 1 | 2021 | 68 | 0.190 |
Why?
| | Corneal Pachymetry | 1 | 2020 | 5 | 0.180 |
Why?
| | Lasers, Excimer | 1 | 2020 | 3 | 0.180 |
Why?
| | Acanthamoeba | 1 | 2020 | 2 | 0.180 |
Why?
| | Female | 10 | 2025 | 26829 | 0.180 |
Why?
| | Benzamidines | 1 | 2020 | 5 | 0.180 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 9 | 0.180 |
Why?
| | Adult | 6 | 2024 | 13486 | 0.180 |
Why?
| | Ophthalmic Solutions | 1 | 2020 | 20 | 0.180 |
Why?
| | Postoperative Period | 1 | 2020 | 170 | 0.170 |
Why?
| | Retinal Vessels | 1 | 2019 | 15 | 0.170 |
Why?
| | Hypercholesterolemia | 1 | 2019 | 36 | 0.170 |
Why?
| | Intraocular Pressure | 1 | 2019 | 56 | 0.170 |
Why?
| | Receptor, Muscarinic M1 | 1 | 2019 | 1 | 0.160 |
Why?
| | Apolipoproteins E | 1 | 2019 | 55 | 0.160 |
Why?
| | Retinal Ganglion Cells | 1 | 2019 | 14 | 0.160 |
Why?
| | Retinal Artery | 1 | 2019 | 5 | 0.160 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 382 | 0.160 |
Why?
| | RNA, Messenger | 2 | 2019 | 1097 | 0.160 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2018 | 75 | 0.160 |
Why?
| | Norepinephrine | 1 | 2018 | 113 | 0.150 |
Why?
| | Ophthalmic Artery | 1 | 2017 | 3 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2020 | 343 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1356 | 0.140 |
Why?
| | Vasodilator Agents | 1 | 2017 | 98 | 0.140 |
Why?
| | Regeneration | 1 | 2017 | 73 | 0.140 |
Why?
| | Oxidative Stress | 1 | 2019 | 763 | 0.120 |
Why?
| | Postoperative Complications | 1 | 2021 | 1027 | 0.120 |
Why?
| | Immune Tolerance | 2 | 2024 | 84 | 0.110 |
Why?
| | Aging | 1 | 2019 | 674 | 0.110 |
Why?
| | Eye Pain | 2 | 2025 | 5 | 0.110 |
Why?
| | Signal Transduction | 1 | 2018 | 1612 | 0.100 |
Why?
| | Corneal Topography | 2 | 2020 | 6 | 0.090 |
Why?
| | Young Adult | 1 | 2020 | 4052 | 0.090 |
Why?
| | Time Factors | 2 | 2024 | 2909 | 0.060 |
Why?
| | Nerve Regeneration | 1 | 2025 | 21 | 0.060 |
Why?
| | Adoptive Transfer | 1 | 2024 | 30 | 0.060 |
Why?
| | Interleukin-10 | 1 | 2024 | 83 | 0.060 |
Why?
| | Transplantation, Homologous | 1 | 2024 | 140 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2025 | 234 | 0.060 |
Why?
| | Mice, Inbred C3H | 1 | 2024 | 84 | 0.060 |
Why?
| | Tissue Preservation | 1 | 2023 | 6 | 0.060 |
Why?
| | Mechlorethamine | 1 | 2023 | 4 | 0.060 |
Why?
| | Cytoprotection | 1 | 2023 | 34 | 0.060 |
Why?
| | Neutrophil Infiltration | 1 | 2023 | 26 | 0.060 |
Why?
| | Cell Movement | 1 | 2024 | 245 | 0.050 |
Why?
| | Antigen-Presenting Cells | 1 | 2023 | 24 | 0.050 |
Why?
| | Microscopy, Confocal | 1 | 2023 | 83 | 0.050 |
Why?
| | Streptozocin | 1 | 2023 | 24 | 0.050 |
Why?
| | Vision Disorders | 1 | 2023 | 59 | 0.050 |
Why?
| | Monocytes | 1 | 2023 | 131 | 0.050 |
Why?
| | Fluorescein | 1 | 2022 | 8 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2022 | 12 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2022 | 107 | 0.050 |
Why?
| | Wound Healing | 1 | 2023 | 203 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2022 | 176 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2024 | 5203 | 0.050 |
Why?
| | Phenotype | 1 | 2024 | 732 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2023 | 257 | 0.050 |
Why?
| | Cell Line | 1 | 2023 | 1010 | 0.050 |
Why?
| | Photorefractive Keratectomy | 1 | 2020 | 2 | 0.050 |
Why?
| | Macrophages | 1 | 2023 | 362 | 0.050 |
Why?
| | Re-Epithelialization | 1 | 2020 | 1 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 2020 | 18 | 0.040 |
Why?
| | Hypertrophy | 1 | 2020 | 49 | 0.040 |
Why?
| | Prednisolone | 1 | 2020 | 55 | 0.040 |
Why?
| | Cadaver | 1 | 2020 | 96 | 0.040 |
Why?
| | Perfusion | 1 | 2019 | 48 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2021 | 210 | 0.040 |
Why?
| | Gene Expression | 1 | 2022 | 612 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 55 | 0.040 |
Why?
| | Eye Proteins | 1 | 2019 | 17 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 183 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2019 | 59 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 317 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 226 | 0.040 |
Why?
| | RNA | 1 | 2019 | 166 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2019 | 178 | 0.040 |
Why?
| | Acetylcholine | 1 | 2017 | 54 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2017 | 25 | 0.040 |
Why?
| | Potassium Channels | 1 | 2017 | 33 | 0.040 |
Why?
| | Catalase | 1 | 2017 | 68 | 0.040 |
Why?
| | Cell Survival | 1 | 2019 | 590 | 0.040 |
Why?
| | Blood Pressure | 1 | 2019 | 527 | 0.040 |
Why?
| | Cytokines | 1 | 2019 | 607 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 2609 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2017 | 259 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1580 | 0.030 |
Why?
| | Risk Factors | 1 | 2022 | 3644 | 0.030 |
Why?
| | Models, Biological | 1 | 2017 | 722 | 0.030 |
Why?
|
|
Musayeva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|